MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Chemistry World
November 2010
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? mark for My Articles similar articles
Chemistry World
March 2011
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. mark for My Articles similar articles
Chemistry World
September 2010
Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase mark for My Articles similar articles
The Motley Fool
February 10, 2011
Brian Orelli
Breathe Easier, Join the Competition Novartis' strategy is a good one. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles similar articles
The Motley Fool
September 20, 2010
Brian Orelli
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. mark for My Articles similar articles
Chemistry World
May 2009
Column: In the pipeline Derek Lowe considers what we think we know about how drugs work once we've taken them mark for My Articles similar articles
Chemistry World
September 2007
Derek Lowe
Column: In the Pipeline Will Phase Zero trials actually help drug development? mark for My Articles similar articles
The Motley Fool
October 18, 2010
Brian Orelli
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. mark for My Articles similar articles
The Motley Fool
July 12, 2010
Ryan McBride
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. mark for My Articles similar articles
The Motley Fool
May 26, 2011
Brian Orelli
Congress Sets Bad Precedent With AVANIR What happened to free markets? mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. mark for My Articles similar articles
The Motley Fool
August 31, 2010
Brian Orelli
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. mark for My Articles similar articles
Bio-IT World
April 2007
Malorye Allison
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. mark for My Articles similar articles
The Motley Fool
March 3, 2011
Brian Orelli
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. mark for My Articles similar articles
Chemistry World
November 18, 2010
Ned Stafford
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2005
Parker & Amar
Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. mark for My Articles similar articles
The Motley Fool
December 9, 2010
Brian Orelli
Here Comes Another Oral MS Drug Good for Teva, bad for the rest. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
The Motley Fool
December 3, 2010
Brian Orelli
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. mark for My Articles similar articles
The Motley Fool
January 7, 2010
Brian Orelli
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. mark for My Articles similar articles
The Motley Fool
September 23, 2010
Brian Orelli
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. mark for My Articles similar articles
The Motley Fool
January 21, 2010
Brian Orelli
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? mark for My Articles similar articles
Chemistry World
July 2010
Anna Lewcock
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. mark for My Articles similar articles
The Motley Fool
March 23, 2010
Brian Orelli
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. mark for My Articles similar articles
The Motley Fool
June 29, 2010
Brian Orelli
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Brian Orelli
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. mark for My Articles similar articles
The Motley Fool
May 11, 2010
Ryan McBride
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. mark for My Articles similar articles
The Motley Fool
June 23, 2010
Brian Orelli
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. mark for My Articles similar articles
Chemistry World
March 27, 2013
Eugene Gerden
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. mark for My Articles similar articles
The Motley Fool
March 29, 2010
Brian Orelli
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2010
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. mark for My Articles similar articles
The Motley Fool
January 28, 2011
Luke Timmerman
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. mark for My Articles similar articles
BusinessWeek
June 2, 2011
Kresge & Connolly
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. mark for My Articles similar articles
The Motley Fool
October 27, 2010
Ralph Casale
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. mark for My Articles similar articles
The Motley Fool
April 13, 2010
Brian Orelli
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. mark for My Articles similar articles
Chemistry World
January 2012
Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about mark for My Articles similar articles
BusinessWeek
May 27, 2010
Michelle Cortez
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. mark for My Articles similar articles
The Motley Fool
August 30, 2010
Brian Orelli
Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless. mark for My Articles similar articles
Chemistry World
July 16, 2010
Matt Wilkinson
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. mark for My Articles similar articles
The Motley Fool
September 12, 2005
M.D. Mitchell
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. mark for My Articles similar articles
The Motley Fool
April 13, 2011
Brian Orelli
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. mark for My Articles similar articles
The Motley Fool
April 29, 2011
Brian Orelli
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. mark for My Articles similar articles
Chemistry World
May 8, 2008
Hepeng Jia
China to fast track pioneering drugs China is to speed up the approval of groundbreaking new drugs in an effort to encourage innovation in its pharmaceutical sector, a State Food and Drug Administration (SFDA) official has revealed. mark for My Articles similar articles
The Motley Fool
November 26, 2007
Brian Lawler
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. mark for My Articles similar articles
Bio-IT World
November 14, 2003
John Dodge
Pfizer's Man with the R&D Plan As Pfizer senior vice president, science and technology, Peter B. Corr oversees $7.1 billion in annual research and development spending, the biggest private R&D budget in the world. In this interview, Corr talks about IT, clinical trials, and his $7-billion budget. mark for My Articles similar articles
BusinessWeek
July 30, 2007
Arlene Weintraub
Is Merck's Medicine Working? Spurred by the Vioxx fiasco, CEO Clark is trying to revamp the drug giant's culture. Analysts expect Merck's top line to grow 4%, to $23.5 billion this year, an achievement considering that sales growth had flatlined even before Vioxx imploded. mark for My Articles similar articles